Xu Huang

P1.074. SNORD33-Driven 18S rRNA 2′-O-Methylation Licenses TNFSF9–4-1BB Signaling and Sensitizes ESCC to PD-1 Blockade

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant PD-1/PD-L1 based immunotherapy improve outcomes for resectable esophageal squamous cell carcinoma (ESCC), but patient outcome are heterogeneous and robust pretreatment blood biomarkers ar...

P1.059. Calcium-Channel Blocker Use and Survival After Neoadjuvant Therapy for Locally Advanced ESCC

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Calcium-channel blockers (CCBs) are commonly prescribed for cardiovascular disease. Beyond hemodynamic effects, experimental studies suggest that CCBs may modulate tumor biology through interference...

OA03-RF01.07. Neoadjuvant Chemoimmunotherapy Versus Upfront Surgery for Clinical T2N0 Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The role of neoadjuvant chemoimmunotherapy (nICT) in clinical T2N0 (cT2N0) esophageal squamous cell carcinoma (ESCC) remains controversial. Current guidelines recommend upfront surgery for this popul...

P1.057. Early Recurrence After Neoadjuvant Therapy and Esophagectomy for Locally Advanced ESCC

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Despite improved interventions with radical esophagectomy accompanied by perioperative systematic therapy, recurrence remains frequent in locally advanced esophageal squamous cell carcinoma (ESCC). A...

P1.058. Angiotensin System Inhibitors and Outcomes After Neoadjuvant Therapy for Locally Advanced ESCC

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Renin angiotensin system signaling has been implicated in tumor growth, angiogenesis, immune modulation, and responses to cytotoxic and radiation-based therapies, yet clinical effects appear heteroge...